^
    Back
    Association details:
    Biomarker:MET overexpression
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:Erbitux (cetuximab) (EGFR inhibitor) +
    ficlatuzumab (AV-299) (c-MET inhibitor, Hepatocyte growth factor inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Clin Oncol
    Title:

    Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer

    Published date:
    03/28/2023
    Excerpt:
    The ficlatuzumab-cetuximab arm met significance criteria for PFS and warrants phase III development. HPV-negative HNSCC merits consideration as a selection criterion….cMet overexpression was associated with reduced hazard of progression in HPV-negative but not HPV-positive disease (P interaction = .02).
    DOI:
    10.1200/JCO.22.01994
    Trial ID:
    P30CA023074